Medical - Healthcare Information Services
Compare Stocks
4 / 10Stock Comparison
SLP vs SCYX vs CRL vs ICLR
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Diagnostics & Research
Medical - Diagnostics & Research
SLP vs SCYX vs CRL vs ICLR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Drug Manufacturers - Specialty & Generic | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $324M | $42M | $8.98B | $9.54B |
| Revenue (TTM) | $79M | $21M | $4.03B | $8.10B |
| Net Income (TTM) | $-64M | $-9M | $-185M | $599M |
| Gross Margin | 59.6% | 9.5% | 24.9% | 26.9% |
| Operating Margin | -89.2% | -77.9% | 11.8% | 12.2% |
| Forward P/E | 18.0x | — | 16.4x | 10.5x |
| Total Debt | $616K | $2M | $3.07B | $3.60B |
| Cash & Equiv. | $31M | $21M | $214M | $539M |
SLP vs SCYX vs CRL vs ICLR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Simulations Plus, I… (SLP) | 100 | 31.7 | -68.3% |
| SCYNEXIS, Inc. (SCYX) | 100 | 12.7 | -87.3% |
| Charles River Labor… (CRL) | 100 | 101.3 | +1.3% |
| ICON Public Limited… (ICLR) | 100 | 74.2 | -25.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLP vs SCYX vs CRL vs ICLR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SLP is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 4 yrs, beta 1.25
- Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 7.67x
SCYX is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 449.9%, EPS growth 61.4%, 3Y rev CAGR 59.4%
- Beta 0.78, current ratio 7.04x
- 449.9% revenue growth vs CRL's -0.9%
- Beta 0.78 vs ICLR's 1.60, lower leverage
CRL is the clearest fit if your priority is long-term compounding.
- 119.2% 10Y total return vs ICLR's 91.0%
- +32.8% vs SLP's -44.6%
ICLR carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (10.5x vs 16.4x)
- 7.4% margin vs SLP's -81.7%
- 3.6% ROA vs SLP's -46.6%, ROIC 6.5% vs -39.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 449.9% revenue growth vs CRL's -0.9% | |
| Value | Lower P/E (10.5x vs 16.4x) | |
| Quality / Margins | 7.4% margin vs SLP's -81.7% | |
| Stability / Safety | Beta 0.78 vs ICLR's 1.60, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +32.8% vs SLP's -44.6% | |
| Efficiency (ROA) | 3.6% ROA vs SLP's -46.6%, ROIC 6.5% vs -39.6% |
SLP vs SCYX vs CRL vs ICLR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SLP vs SCYX vs CRL vs ICLR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ICLR leads in 2 of 6 categories
CRL leads 1 • SLP leads 1 • SCYX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — SLP and SCYX and ICLR each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ICLR is the larger business by revenue, generating $8.1B annually — 393.3x SCYX's $21M. ICLR is the more profitable business, keeping 7.4% of every revenue dollar as net income compared to SLP's -81.7%. On growth, SCYX holds the edge at +18.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $79M | $21M | $4.0B | $8.1B |
| EBITDAEarnings before interest/tax | -$63M | $11M | $757M | $1.4B |
| Net IncomeAfter-tax profit | -$64M | -$9M | -$185M | $599M |
| Free Cash FlowCash after capex | $23M | -$5M | $391M | $996M |
| Gross MarginGross profit ÷ Revenue | +59.6% | +9.5% | +24.9% | +26.9% |
| Operating MarginEBIT ÷ Revenue | -89.2% | -77.9% | +11.8% | +12.2% |
| Net MarginNet income ÷ Revenue | -81.7% | -41.8% | -4.6% | +7.4% |
| FCF MarginFCF ÷ Revenue | +29.2% | -25.6% | +9.7% | +12.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.7% | +18.1% | +1.2% | +0.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | +3.3% | -160.0% | -98.7% |
Valuation Metrics
ICLR leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, ICLR's 7.9x EV/EBITDA is more attractive than CRL's 13.0x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $324M | $42M | $9.0B | $9.5B |
| Enterprise ValueMkt cap + debt − cash | $293M | $23M | $11.8B | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | -4.99x | -5.63x | -62.52x | 13.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.01x | — | 16.42x | 10.53x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.87x |
| EV / EBITDAEnterprise value multiple | — | — | 12.98x | 7.95x |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 2.02x | 2.24x | 1.15x |
| Price / BookPrice ÷ Book value/share | 2.59x | 0.97x | 2.81x | 1.09x |
| Price / FCFMarket cap ÷ FCF | 18.58x | — | 17.31x | 8.53x |
Profitability & Efficiency
ICLR leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ICLR delivers a 6.3% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for SLP. SLP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs CRL's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -50.5% | -19.0% | -5.7% | +6.3% |
| ROA (TTM)Return on assets | -46.6% | -14.4% | -2.5% | +3.6% |
| ROICReturn on invested capital | -39.6% | -28.2% | +6.3% | +6.5% |
| ROCEReturn on capital employed | -44.1% | -26.8% | +8.1% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.04x | 0.95x | 0.38x |
| Net DebtTotal debt minus cash | -$30M | -$19M | $2.9B | $3.1B |
| Cash & Equiv.Liquid assets | $31M | $21M | $214M | $539M |
| Total DebtShort + long-term debt | $616,000 | $2M | $3.1B | $3.6B |
| Interest CoverageEBIT ÷ Interest expense | — | -20.98x | 6.38x | 3.96x |
Total Returns (Dividends Reinvested)
CRL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ICLR five years ago would be worth $5,463 today (with dividends reinvested), compared to $1,393 for SCYX. Over the past 12 months, CRL leads with a +32.8% total return vs SLP's -44.6%. The 3-year compound annual growth rate (CAGR) favors CRL at -1.4% vs SCYX's -31.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.3% | +49.8% | -10.1% | -33.7% |
| 1-Year ReturnPast 12 months | -44.6% | -0.4% | +32.8% | -10.0% |
| 3-Year ReturnCumulative with dividends | -59.6% | -67.9% | -4.2% | -34.1% |
| 5-Year ReturnCumulative with dividends | -70.5% | -86.1% | -46.9% | -45.4% |
| 10-Year ReturnCumulative with dividends | +104.0% | -97.6% | +119.2% | +91.0% |
| CAGR (3Y)Annualised 3-year return | -26.0% | -31.5% | -1.4% | -13.0% |
Risk & Volatility
Evenly matched — SCYX and CRL each lead in 1 of 2 comparable metrics.
Risk & Volatility
SCYX is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than ICLR's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRL currently trades 79.5% from its 52-week high vs SLP's 47.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.78x | 1.52x | 1.60x |
| 52-Week HighHighest price in past year | $34.01 | $1.31 | $228.88 | $211.00 |
| 52-Week LowLowest price in past year | $11.09 | $0.56 | $131.30 | $66.57 |
| % of 52W HighCurrent price vs 52-week peak | +47.2% | +73.1% | +79.5% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 67.9 | 51.3 | 57.2 | 62.1 |
| Avg Volume (50D)Average daily shares traded | 315K | 571K | 806K | 1.1M |
Analyst Outlook
SLP leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SLP as "Buy", CRL as "Buy", ICLR as "Buy". Consensus price targets imply 248.7% upside for SLP (target: $56) vs 12.9% for CRL (target: $205).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $56.00 | — | $205.43 | $149.63 |
| # AnalystsCovering analysts | 8 | — | 36 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 4 | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.0% | +5.2% |
ICLR leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). CRL leads in 1 (Total Returns). 2 tied.
SLP vs SCYX vs CRL vs ICLR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SLP or SCYX or CRL or ICLR a better buy right now?
For growth investors, SCYNEXIS, Inc.
(SCYX) is the stronger pick with 449. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Simulations Plus, Inc. (SLP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLP or SCYX or CRL or ICLR?
On forward P/E, ICON Public Limited Company is actually cheaper at 10.
5x.
03Which is the better long-term investment — SLP or SCYX or CRL or ICLR?
Over the past 5 years, ICON Public Limited Company (ICLR) delivered a total return of -45.
4%, compared to -86. 1% for SCYNEXIS, Inc. (SCYX). Over 10 years, the gap is even starker: CRL returned +119. 2% versus SCYX's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLP or SCYX or CRL or ICLR?
By beta (market sensitivity over 5 years), SCYNEXIS, Inc.
(SCYX) is the lower-risk stock at 0. 78β versus ICON Public Limited Company's 1. 60β — meaning ICLR is approximately 104% more volatile than SCYX relative to the S&P 500. On balance sheet safety, Simulations Plus, Inc. (SLP) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SLP or SCYX or CRL or ICLR?
By revenue growth (latest reported year), SCYNEXIS, Inc.
(SCYX) is pulling ahead at 449. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: SCYNEXIS, Inc. grew EPS 61. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, SCYX leads at 59. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SLP or SCYX or CRL or ICLR?
ICON Public Limited Company (ICLR) is the more profitable company, earning 9.
6% net margin versus -81. 7% for Simulations Plus, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus -89. 3% for SLP. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SLP or SCYX or CRL or ICLR more undervalued right now?
On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10.
5x forward P/E versus 18. 0x for Simulations Plus, Inc. — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SLP: 248. 7% to $56. 00.
08Which pays a better dividend — SLP or SCYX or CRL or ICLR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SLP or SCYX or CRL or ICLR better for a retirement portfolio?
For long-horizon retirement investors, SCYNEXIS, Inc.
(SCYX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SCYX: -97. 6%, ICLR: +91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SLP and SCYX and CRL and ICLR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SLP is a small-cap quality compounder stock; SCYX is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.